Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

被引：3

作者：

Schlick, Konstantin ^{[1
,2
,3
]}

Hohla, Florian ^{[1
]}

Hamacher, Frank ^{[2
,3
]}

Hackl, Hubert ^{[5
]}

Hufnagl, Clemens ^{[1
,2
,3
]}

Markus, Steiner ^{[1
,2
,3
,4
]}

Magnes, Teresa ^{[1
,2
,3
]}

Gampenrieder, Simon Peter ^{[1
,2
,3
,4
]}

Melchardt, Thomas ^{[1
,2
,3
,4
]}

Staettner, Stefan ^{[6
,7
]}

Hauser-Kronberger, Cornelia ^{[8
]}

Greil, Richard ^{[1
,2
,3
,4
]}

Rinnerthaler, Gabriel ^{[1
,2
,3
,4
]}

机构：

[1] Paracelsus Med Univ Salzburg, Oncol Ctr, Med Dept 3, Hematol & Med Oncol Hemostaseol Rheumatol & Infec, Milner Hauptstr 48, A-5020 Salzburg, Austria

[2] Salzburg Canc Res Inst, Lab Immunol & Mol Canc Res, Salzburg, Austria

[3] Ctr Clin Canc & Immunol Trials, Salzburg, Austria

[4] Canc Cluster Salzburg, Salzburg, Austria

[5] Med Univ Innsbruck, Bioctr, Div Bioinformat, Innsbruck, Austria

[6] Salzkammergutklinikum, Dept Surg, Standort Vocklabruck, Oberosterreich, Austria

[7] Paracelsus Med Univ Salzburg, Dept Surg, Salzburg, Austria

[8] Paracelsus Med Univ Salzburg, Dept Pathol, Salzburg, Austria

来源：

FUTURE SCIENCE OA | 2021年 / 7卷 / 02期

关键词：

FOLFIRINOX; gemcitabine; miRNA; pancreatic cancer; SURVIVAL; ADENOCARCINOMA; DIAGNOSIS; CRITERIA; THERAPY; MIR-21;

D O I：

10.2144/fsoa-2020-0128

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-5p, miR-10b-5p and miR-34a-5p have been previously linked to a worse response to gemcitabine. We investigated the influence of expression levels in tumor tissue of those three microRNAs on outcome to FOLFIRINOX. Twenty-nine patients with sufficient formalin-fixed paraffin-embedded tumor tissue were identified. There was no significant association between high and low expression groups for these three microRNA. We conclude that polychemotherapy combination can overcome intrinsic negative prognostic factors. Lay abstract: Treatment outcome with the polychemotherapy FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but FOLFIRINOX can cause severe toxicities. Therefore, we investigated biomarkers that may guide treatment decision. Altered expression of certain microRNAs, small noncoding RNAs, are associated with a worse response to gemcitabine. We found that the expression of the microRNAs miR-21-5p, miR-10b-5p and miR-34a-5p have no preditive value in patients treated with FOLFIRINOX. We therefore, conclude that polychemotherapy combination can overcome intrinsic negative prognostic factors.

引用

页数：8

共 43 条

[1] The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance [J].

Biancur, Douglas E. ;

Kimmelman, Alec C. .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (01) :67-75

[2] MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis [J].

Bloomston, Mark ;

Frankel, Wendy L. ;

Petrocca, Fabio ;

Volinia, Stefano ;

Alder, Hansjuerg ;

Hagan, John P. ;

Liu, Chang-Gong ;

Bhatt, Darshna ;

Taccioli, Cristian ;

Croce, Carlo M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (17) :1901-1908

[3] MicroRNA signatures in human cancers [J].

Calin, George A. ;

Croce, Carlo M. .

NATURE REVIEWS CANCER, 2006, 6 (11) :857-866

[4] MicroRNA-cancer connection: The beginning of a new tale [J].

Calin, George Adrian ;

Croce, Carlo Maria .

CANCER RESEARCH, 2006, 66 (15) :7390-7394

[5] The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms [J].

Caponi, S. ;

Funel, N. ;

Frampton, A. E. ;

Mosca, F. ;

Santarpia, L. ;

Van der Velde, A. G. ;

Jiao, L. R. ;

De Lio, N. ;

Falcone, A. ;

Kazemier, G. ;

Meijer, G. A. ;

Verheul, H. M. ;

Vasile, E. ;

Peters, G. J. ;

Boggi, U. ;

Giovannetti, E. .

ANNALS OF ONCOLOGY, 2013, 24 (03) :734-741

[6] Gene regulation by RNA binding proteins and microRNAs in angiogenesis [J].

Chang, Sung-Hee ;

Hla, Timothy .

TRENDS IN MOLECULAR MEDICINE, 2011, 17 (11) :650-658

[7] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].

Conroy, T. ;

Hammel, P. ;

Hebbar, M. ;

Ben Abdelghani, M. ;

Wei, A. C. ;

Raoul, J. -L. ;

Chone, L. ;

Francois, E. ;

Artru, P. ;

Biagi, J. J. ;

Lecomte, T. ;

Assenat, E. ;

Faroux, R. ;

Ychou, M. ;

Volet, J. ;

Sauvanet, A. ;

Breysacher, G. ;

Di Fiore, F. ;

Cripps, C. ;

Kavan, P. ;

Texereau, P. ;

Bouhier-Leporrier, K. ;

Khemissa-Akouz, F. ;

Legoux, J. -L. ;

Juzyna, B. ;

Gourgou, S. ;

O'Callaghan, C. J. ;

Jouffroy-Zeller, C. ;

Rat, P. ;

Malka, D. ;

Castan, F. ;

Bachet, J. -B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406

[8] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[9] Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].

Ducreux, M. ;

Cuhna, A. Sa. ;

Caramella, C. ;

Hollebecque, A. ;

Burtin, P. ;

Goere, D. ;

Seufferlein, T. ;

Haustermans, K. ;

Van Laethem, J. L. ;

Conroy, T. ;

Arnold, D. .

ANNALS OF ONCOLOGY, 2015, 26 :V56-V68

[10] Oncomirs - microRNAs with a role in cancer [J].

Esquela-Kerscher, A ;

Slack, FJ .

NATURE REVIEWS CANCER, 2006, 6 (04) :259-269

← 1 2 3 4 5 →